Safety assessment of the Yeast Extract containing nicotinamide mononucleotide (NMN)
- Conditions
- Healthy volunteer
- Registration Number
- JPRN-UMIN000039527
- Lead Sponsor
- niversity of Toyama
- Brief Summary
This clinical trial is terminated.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 0
Not provided
1. Person with past treatment history of malignant tumor, heart failure, or myocardial infarction. 2. Person currently under treatment for atrial fibrillation, arrhythmia, hepatic dysfunction, renal dysfunction, cerebrovascular disorder, rheumatism, diabetes, dyslipidemia, hypertension, or other chronic diseases.3. Person with medication (including Kampo medicine). 4. Person with allergy against medicine or the test food 5. Pregnant, unwilling to practice contraception during the study, or lactating female 6. Person who is not judged as not qualified by the medical doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Safety assessment (1) Physical measurements height, weight, body fat percentage, BMI, systolic blood pressure, diastolic blood pressure, heart rate (2) Blood test hematology: white blood cell count, red blood cell count, hemoglobin, Hematocrit, platelet count, MCV, MCH, MCHC b. Biochemical tests: TG, total cholesterol, LDL-cholesterol, HDL-cholesterol, free fatty acid, acetoacetic acid, 3-hydroxyacetic acid, total ketone body , lipoprotein (a), glucose, HbA1c, insulin, AST , AL T, gamma-GTP, ALP, LDH, total protein, albumin, uric acid, urea nitrogen, creatinine, sodium, chloride, potassium, calcium, inorganic phosphorus, magnesium (3) Urine testing Sugar, protein, urobilinogen, ketone body, pH, specific gravity, occult blood reaction, bilirubin, sediment (when protein is positive) (4) Diary
- Secondary Outcome Measures
Name Time Method Assessment the NAD-related metabolites in blood Blood NAD,NMN,nicotinamide,NA,NR,NAR,NAMN,NAAD